Guyana vs Russian Federation: Average cost of multi drug-resistant tuberculosis treatment
Guyana
2,586 constant 2022 US$
in 2024
Russian Federation
2,751 constant 2022 US$
in 2024
Guyana rank
19th
Russian Federation rank
18th
Average cost of multi drug-resistant tuberculosis treatment over time
- Guyana
- Russian Federation
How they compare
Russian Federation currently reports 2,751 constant 2022 US$ against 2,586 constant 2022 US$ in Guyana, a difference of 165 constant 2022 US$.
That makes Russian Federation's figure about 1.1 times Guyana's.
Across all 6 years both countries report, Russian Federation has been ahead every year.
Guyana ranks 19th and Russian Federation ranks 18th of 92 countries.
Russian Federation has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guyana | Russian Federation | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,450 constant 2022 US$ | 2,807 constant 2022 US$ | 1,356 constant 2022 US$ | Russian Federation |
| 2020s | 1,847 constant 2022 US$ | 2,819 constant 2022 US$ | 971.75 constant 2022 US$ | Russian Federation |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Guyana or Russian Federation?
- Russian Federation, at 2,751 constant 2022 US$ against 2,586 constant 2022 US$ in Guyana as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Guyana and Russian Federation?
- 165 constant 2022 US$, with Russian Federation ahead.
- How many years of comparable data are there for Guyana and Russian Federation?
- 6 years are reported by both, from 2017 to 2024.
- How do Guyana and Russian Federation rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Guyana ranks 19th and Russian Federation ranks 18th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.